PharmaLegacy

PharmaLegacy is a Shanghai-based contract research organization (CRO) specializing in nonclinical pharmacology. This article provides an overview of the company’s core strengths, its portfolio of disease models, and representative preclinical study examples.

Features of PharmaLegacy’s Contract Services for Non-Clinical Studies

Extensive experience supporting IND submissions to the FDA and CFDAP

PharmaLegacy has supported numerous clients in filingInvestigational New Drug (IND) applications with both the U.S. Food and Drug Administration (FDA) and the China Food and Drug Administration (CFDA).
The company’s animal facilities are fully accredited by AAALAC International and house a broad range of species, including rodents, rabbits, other small laboratory animals, and non-human primates (NHPs). All operations are conducted in accordance with GLP standards and quality assurance (QA) best practices.

Large-scale animal facilities with strong capabilities in NHP studies

With particular strengths in non-human primate studies, PharmaLegacy operatesa 380,000-square-foot facilitythat includes120,000 square feet of SPF and conventional animal housing space.The facility can accommodate up to 350 NHPs, as well as approximately 30,000 rodents and large laboratory animals.

Robust PK/PD study capabilities

PharmaLegacy’s PK/PD research is built on a set of core principles, including appropriate animal model selection and handling, ethical dosing and administration practices, and accurate efficacy assessment across multiple disease models.
The company’s diverse portfolio of validated models is designed around these principles, enabling clients to generatePK/PD data with strong scientific validity and translational relevance.

Examples of Disease Models Available at PharmaLegacy

PharmaLegacy maintains a portfolio of more than 1,500 validated animal modelscovering a wide range of therapeutic areas, including oncology, bone diseases, autoimmune disorders, and inflammatory conditions.
For example, the company offers multiple preclinical models of acute renal disease, allowing for detailed evaluation of treatment effects on disease pathophysiology. In addition, PharmaLegacy provides carefully engineered heart failure models—such as myocardial infarction, myocardial ischemia–reperfusion, and pressure overload–induced hypertrophy—designed to closely recapitulate human cardiac pathology.

PharmaLegacy Non-Clinical Case Study

MCD diet–induced NASH model

PharmaLegacy’s non-alcoholic steatohepatitis (NASH) models offer flexible options tailored to the specific disease characteristics under investigation. In one representative study,a NASH model was established in male Wistar rats by feeding a methionine- and choline-deficient (MCD) diet for eight weeks, resulting in the induction of NASH.Following disease establishment, animals were treated with either vehicle or a reference compound over an additional eight-week study period.

PharmaLegacy Company Information

PharmaLegacy is a China-based CRO with extensive experience, a broad range of validated disease models, and deep expertise in nonclinical pharmacology. The company’s scientific staff has an average of more than 15 years of experience in pharmacological research, enabling the generation of high-quality and reliable pharmacology data across multiple disease areas.